Skip to main content

Advertisement

  • Research
  • Open Access

The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro

  • †1, 2,
  • †1, 2,
  • 1, 2Email author,
  • 1, 2,
  • 1, 2 and
  • 1, 2
†Contributed equally
Journal of Experimental & Clinical Cancer Research200928:123

https://doi.org/10.1186/1756-9966-28-123

©  Zhuang et al; licensee BioMed Central Ltd. 2009

  • Received: 18 January 2009
  • Accepted: 1 September 2009
  • Published:

Abstract

Background

Despite of the recent success of EGFR inhibitory agents, the primary drug-resistant becomes a major challenge for EGFR inhibitor therapies. PTEN gene is an important positive regulatory factor for response to EGFR inhibitor therapy. Low-expression of PTEN is clearly one of the important reasons why tumor cells resisted to tyrosine kinase inhibitors.

Methods

To investigate the drug-resistance reversal to gefitinb and the mechanism in PTEN low expression cells which radiated with X-rays in vitro, We demonstrated that H-157 lung cancer cells (low-expression of PTEN but phospho-EGFR overexpressed tumor cells) exposed to X-rays. The PTEN expressions and radiosensitizing effects of tyrosine kinase inhibitor before and after irradiation were observed. The cell-survival rates were evaluated by colony-forming assays. The cell apoptosis was investigated using FCM. The expressions of phospho-EGFR and PTEN were determined by Western blot analysis.

Results

The results showed that the PTEN expressions were significantly enhanced by X-rays. Moreover, the cell growth curve and survival curve were down-regulated in the gefitinib-treated groups after irradiation. Meanwhile, the radiation-induced apoptosis of tumor cells was increased by inhibition of the EGFR through up-regulation of PTEN.

Conclusion

These results suggested that PTEN gene is an important regulator on TKI inhibition, and the resistance to tyrosine kinase inhibitors might be reversed by irradiation in PTEN low expression cancer cells.

Keywords

  • Gefitinib
  • Tyrosine Kinase Inhibitor
  • PTEN Expression
  • Cell Growth Curve
  • Gefitinib Group

Background

The EGFR is a receptor tyrosine kinase that regulates fundamental processes of cell growth and differentiation. Overexpression of EGFR and its ligands, were reported for various epithelial tumors in the 1980s [1, 2] and generated interest in EGFR as a potential target for cancer therapy [3–9]. These efforts have been rewarded in recent years as ATP site-directed EGFR tyrosine kinase inhibitors has shown anti-tumor activity in subsets of patients with non-small cell lung cancer [10, 11], squamous cell carcinomas of the head and neck [12], and selected other malignancies [13–17]. The current data from retrospectively analyzed clinical trials and preclinical models [18–23] suggested that monotherapy with EGFR kinase inhibitors is unlikely to be effective in PTEN-deficient tumors, even if they harbor activating EGFR mutations. This could potentially result in upfront resistance to EGFR inhibitors in highly PTEN-deficient tumors. However, there are little research on the drug-resistance of EGFR kinase inhibitors, and there is no suitable means for reversal of drug resistance in clinical practice until today. The data presented herein describe the resistance to tyrosine kinase inhibitors (TKI) reversed on PTEN low-expression cancer cells by irradiation in vitro. Our study may have potential impacts on the clinical applications of combining TKI with irradiation therapy in patients with cancers of primary drug-resistance to TKI.

Materials and methods

Reagents

Cell culture media was provided by Tianjin Medical University Cancer Institute (Jin-pu Yu, MD). Primary antibodies against phospho-EGFR and PTEN were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); Propidium Iodide (PI) and annexin V were purchased from Cell Signaling Company (Cell Signaling Technology, Beverly, MA). Gefitinib was generously provided by AstraZeneca (Zhen-yu You, Beijing). All the other materials were from Cancer Institute of our university.

Cell lines and cell culture

The H-157 lung cancer cell line was kindly provided by Peking University Center for Human Disease Genomics. It was maintained in RPMI1640 supplemented with 20 mM HEPES (pH 7.4), 100 IU/mL penicillin, 100 mg/mL streptomycin, 4 mM glutamine and 10% heat-inactivated fetal bovine serum (Hangzhou Sijiqing Biological Engineering Materials Company, China) in a humidified atmosphere of 95% air and 5% CO2 at 37°C.

Ionizing radiation treatment

Exponentially growing H-157 cells in a tissue-culture flask (75 cm2) were irradiated by an X-ray generator with a 1.0-mm aluminum filter at 200 kVp and 10 mA, at a dose of 1.953 Gy/min, which was determined using Fricke's chemical dosimeter. Then they were incubated for another 48 h at 37°C. Addition of Gefitinib was carried out at the same time when the treatment of irradiation was performed. Radiation was performed in the Tianjin Medical University Cancer hospital.

Western blot analysis

To examine the phospho-EGFR and PTEN expression in H-157 cells, the protein was assayed by western blot analysis [24]. To determine whether irradiation causes an increase of PTEN expression, cells in culture were irradiated with 1, 2, 4, 6, 8 and 10 Gy. Following treatment, the cells were collected 3 h, 6 h, 9 h, and 12 h respectively. Total protein was extracted from H-157 cancer cell lines, resolved and analyzed by Western blotting. In brief, cells were washed with cold-phosphate buffered saline (PBS), scraped in RIPA buffer (100 mMTris, 5 mMEDTA, 5%NP40, pH8.0) containing protease inhibitors cocktail (Roche diagnostics, Mannheim, Germany) and allowed for at least 30 min on ice. Cells were subjected to further analysis by one freeze-thaw cycle and centrifuged at 14,000 g for 30 min at 4°C. Supernatants were carefully removed and protein concentrations were determined by Bio-Rad-DC protein estimation kit. Electrophoresis was performed on polyacrylamide gel (10%) using equal amounts of protein samples under reducing conditions. Resolved proteins were transferred to the PVDF membranes and probed with primary antibodies followed by incubation with corresponding horseradish peroxidase-conjugated secondary antibodies. Signal was detected with ECL electrochemiluminescence (ECL) Kit (Amersham Biosciences).

Cell-growth analysis

Cell proliferation was determined by assessing the mitochondrial reduction of MTT. In brief, cells from the control and gefitinib-pre-treated groups were plated at 1 × 103 cells/well in 96-well plates containing 200 μL growth medium and allowed to attach for 24 h. The medium was removed, and the gefitinib-treated cells were quiesced for 2d in a medium supplemented with100, 500, 1000 nM gefitinib. The medium was changed on day 2 of the 4d experiment. At harvest, the medium was removed from the appropriate wells, replaced with 50 μL MTT solution (2.5 mg MTT/ml), and incubated for 4 h at 37°C. After incubation, the MTT solution was carefully aspirated and replaced with 150 μL DMSO. Cell growth was analyzed on a plate reader by using SoftMax program (Molecular Devices Corp., Menlo Park, CA). Experiments were performed in quadruplicate and repeated at least 3 times. At the same time, the antiproliferative effect of gefitinib on the growth profile in vitro of H-157 cell line was examined. Briefly, The cells were treated with different concentrations of gefitinib (100, 500, 1000 nM). The control and gefitinib-treated cells(1 × 104/well) were seeded on 6-well plates, and proliferation was evaluated by cell counting using a hemocytometer after 1,2,3,4,5,6 and 7 days of culture. All measurements were done in triplicate [25, 26]. The methods were also used to detect the antiproliferative effect of gefitinib after irradiation.

Clonogenic survival

Clonogenic survival was the ability of cells to maintain clonogenic capacity and to form colonies. The treatment schedule for clone assay: there are 4 groups in the experiments (the control, irradiation and/or gefitinib-treated groups). Cells in culture were irradiated with 1, 2, 4, 6, 8 and 10 Gy, and the gefitinib concentration was 100 nM. Briefly, after exposure to radiation, cells were trypsinized, counted, and seeded for colony formation in 60 mm dishes at 200 to 10000 cells/dish. After incubation intervals of 14 to 21 days, colonies were stained with crystal violet and manually counted. Colonies consisting of 50 cells or more were scored. Experiments were done in triplicate [27].

Detection of apoptotic cells by FCM

To examine whether enhancement of apoptosis in X-ray irradiated H-157 cells overexpressed with PTEN was associated with gefitinib, we tested the effects of EGFR inhibitors on the enhancement of apoptosis in H-157 cells with and without irradiation. Cells from the irradiation and combined with Gefitinib groups (100 nM) were exposed to the same radiation dosages (6 Gy). At 48 h after irradiation, the cells were harvested. And then, cells were trypsinized, counted, and washed twice with cold PBS. Cells used for tests were stained with propidium iodide (PI) and annexin V for 15 min in the dark and analyzed by fluorescence-activated cell sorting (FACS) using Coulter EPICS and ModFit software (Verity Software House, Topsham, MN). Each test was performed 3 times [28].

Statistical analysis

Data was plotted as means ± standard deviation. Student's t test was used for comparisons. Differences were considered significant at P < 0.05.

Results

EGFR, PTEN expression of H-157 cells

It was reported that H-157 cells might be overexpression of phospho-EGFR and low-expression of PTEN [18]. In the present study, we confirmed the expression of phospho-EGFR and PTEN on the cells by western blotting. H-157 cells expressed high level of phospho-EGFR, but PTEN was low expressed. Both the phospho-EGFR and PTEN highly expressed cells, the A431 cells, were taken as positive control (Figure 1).
Figure 1
Figure 1

Expressions of EGFR and PTEN in H-157 cells. Western blots of EGFR (upper panel) and PTEN (lower panel) in H-157 cells. Both the EGFR and PTEN highly expressed cells, A431 cells, were taken as positive control.

Effects of gefitinib on H-157 cell growth

As shown in Figure 2, though different concentrations treatment produced no significant inhibition to H-157 cell growth. Cell counting was also used to assess the proliferative ability of gefitinib-treated cells. There was no significant difference in the growth rates between control cells and gefitinib-treated cells.
Figure 2
Figure 2

Effects of gefitinib on H-157 cell growth in vitro. (A)Cell proliferation was determined by assessing the mitochondrial reduction of MTT. Bars indicated means ± standard deviation of three independent experiments performed in triplicate (n = 9). Compared with untreated control cells, P > 0.05 were found in all of the treated groups. (B)Known numbers of single cells were plated into culture dishes in RPMI1640 containing 10% FBS and treated with gefitinib in several doses. Cells were then harvested by trypsinization and counted by a hemocytometer with trypan blue dye. Data points mean of triplicate samples. Data were expressed as means ± SE for three experiments. P> 0.05 vs. control group by Student's t-test was found in every treated group.

Expression of PTEN in H-157 cells after irradiation treatment

After different dosage radiation (0, 1, 2, 4, 6, 8, and 10 Gy), the PTEN expression increased in a time-dependent manner. The highest expression were observed in H-157 cells treated with 4~6 Gy irradiation. At the same time, we also measured that PTEN expression increased at 3 h and returned to baseline at 12 h after irradiation (Figure 3). Based on this, we concluded that 6 Gy was the best dosage for improving PTEN expression and the same time as treatment with irradiation was the optimal time for addition of gefitinib.
Figure 3
Figure 3

Expression of PTEN in H-157 cells after irradiation treatment. (A) The H-157 cells which exposed to 1, 2, 4, 6, 8, and 10 Gy of X-rays were analyzed as shown in right panel. After irradiation, the cells were incubated for 6 h, and then were examined. (B) After incubation of X-irradiated (6 Gy) cells for 3, 6, 9 and 12 h, the PTEN protein was examined by Western blotting. Irradiation Treatment was shown to increase PTEN levels in H-157 cell lines tested, and H-157 cells exposing to 4~6 Gy expressed major amounts of PTEN.

Survival curve and cell growth curve of gefitinib-treated H-157 cells after irradiation

The cloning efficiency of H-157 was between 60% and 90%. The survival curve of control and gefitinib-treated H-157 cells after irradiation was shown in Figure 4. The radiobiological parameters of H-157 cells treated with irradiation and gefitinib were D0 = 1.14, Dq = 0.22, N = 1.57, while those of irradiation-treated H-157 cells were D0 = 1.51, Dq = 0.88, N = 3.84. In the present study, SER (sensitive enhancement ratio) = D0 (irradiation+gefitinib group)/D0 (irradiation group) = 1.51/1.14 = 1.32. The SER in gefitinib-treated cells indicated that treatment with gefitinib significantly improved the biological effect of irradiation following PTEN high expressed. At the same time, the cell growth curve was also down-regulated by gefitinib after irradiation (Figure 4). The data presented herein suggested the resistance for gefitinib was reversed by irradiation in H-157cells.
Figure 4
Figure 4

Irradiation reversed the resistance of H-157 cells to gefitinib. (A) Clonogenic survival curves for gefitinib and/or radiation treatments in H-157 cells. Cells attached to the flasks were treated with 100 nmol/L gefitinib, meanwhile, irradiated with graded doses of x-rays, rinsed after 48-hour incubation in drug-containing medium, and allowed to form colonies in drug-free medium. Surviving fractions for radiation + gefitinib were normalized by dividing by the surviving fraction for gefitinib only. Each test was performed 3 times. The radiation-enhancing (t = 7.65, P < 0.01) effect of gefitinib was comparable with that of gefitinib alone in H-157 cells. (B) Effects of gefitinib on H-157 cell growth after irradiation. There was no significant difference (t = 1.13, P > 0.05) in the growth rates between H-157 cells and gefitinib-treated cells as determined by cell counting, but the proliferative ability of the gefitinib and radiation treated cells was dramatically suppressed(t = 5.01, P < 0.05)in contrast with radiation-treated only.

Gefitinib increased the radiation-induced apoptosis

As shown in Figure 5. The early apoptosis rate among gefitinib-treated H-157 cells after 6 Gy irradiation was significantly higher than the cells with the same dosage of X-rays only. Whereas, no significant apoptotic changes were observed in unirradiated cells before and after gefitinib treated. Quantitative measurements of apoptotic cell death by FCM in H-157 cells sufficiently indicated that the radiation-induced overexpression of PTEN significantly enhanced gefitinib-induced apoptosis in comparison with that of the control (no irradiation).
Figure 5
Figure 5

Gefitinib-induced apoptosis in H-157 cells before and after irradiation. Attached cells were exposed to 6 Gy irradiation and then treated with 100 nmol/L gefitnib. After additional 48-hour incubation in medium containing the drugs, the cells were harvested. The apoptotic index (AI) was measured using flow cytometry. (A) Control groups (AI: 1.36 ± 0.74%). (B) Apoptotic values after treatment with 100 nmol/L gefitinib alone (AI:3.58 ± 0.61%).(C) Radiation- induced apoptosis induction (14.26 ± 2.97%% of total cells) in H-157 cells.(D) Radiation combined with gefitinib induced apoptosis induction (23.58 ± 3.61% of total cells). Apoptotic values were normalized by subtracting control values; the normalized apoptotic values were used for statistical analyses. Experiments were done in triplicate. Combined drug treatments were shown to enhance radiation-induced apoptosis in H-157 cells (t = 19.91, P < 0.01), but no synergistic manner when compared with drug alone without radiation (t = 2.569, P > 0.05).

Discussion

The PI3K pathway is a critical effector of growth, proliferation, and survival pathways. PTEN serves as negative regulator of the phosphatidylinositol 3-kinase (PI3K) pathway by removing the third phosphate from the inositol ring of the second messenger PIP3 [29]. PTEN inactivation results in accumulation of PIP3 levels and persistent signaling through the serine/threonine kinase Akt/protein kinase B. PTEN loss could thus promote resistance to EGFR kinase inhibitors from downstream inhibition of the PI3K signaling pathway [30–35]. Consistent with this, increased levels of PTEN expression is considered as basic principle during reversal of resistance for tyrosine kinase inhibitors in patients with PTEN low-expression cancers. In order to improve PTEN expression, transfection by medium such as plasmid and virus is the common method in fundamental research [36–39]. However, in the clinical application, these methods have been unable to overcome its own errors and defects, for instance, transfection efficiency, distribution in vivo, and so on. Finding the effective methods which can reverse primary drug-resistance in PTEN low-expression cells has become the urgent task on targeted therapy in clinical practice.

As the drug resistant cell line for tyrosine kinase inhibitors due to low expression level of PTEN protein [18], H-157 cell line is the precondition of the experiment. Our results demonstrated that phospho-EGFR higher expression and low-expression of PTEN present in H-157 cells (Fig. 1), which are accorded with the reports of literatures [18]. We also observed that when the H-157 cells were exposed to gefitinib, no significant deference of cell growth curve (Fig. 2), and no increase in the apoptosis of cells was found (Fig. 5). In conclusion, findings from the present study indicated that gefitinib has no effective antiproliferative function for H-157 cells. As a safe and satisfied method in the clinical therapy of cancer, Irradiation is easy to obtained, and it has not the disadvantages such as maldistribution and low transfer efficiency of transfection. Compared with transfection, irradiation possesses incomparable superiority, and it is one of the best solutions of drug-resistant reversal for TKI therapy [40, 41]. Meanwhile, our results indicated that exposure to gefitinib after radiation enhanced the radiosensitivity of H-157 cells (Fig. 4). Considering that an increase in the level of the PTEN expression, the negative regulator of the phosphatidylinositol 3-kinase (PI3K) pathway was increased after irradiation, and then the second messenger PIP3 levels decreased, further activation of the serine/threonine kinase Akt/protein kinase B declined. So, the cell proliferation decreased and the cell death increased [29]. Therefore, x-ray radiation might play a major role in the drug-resistance reversal.

It must point out that cross talk between different pathways makes miscellaneous of signal transductions in tumor cells. Up to now, it is still unclear that whether there exist other factors of PI3K pathway producing influence for tyrosine kinase inhibitors efficacy except for PTEN protein. Whether the factors are influenced by irradiation, and then made some effect on the drug-resistance further remains unknown. These all need further research on PI3K pathway.

Conclusion

Our study provides a new idea for drug-resistance reversal of TKI targeted therapy, and makes a beneficial exploration on tyrosine kinase inhibitors combined with radiotherapy in TKI resistant tumors. We believe that, with the further development of fundamental research, we are looking forward to an increasing application prospect of tyrosine kinase inhibitors in clinical practice.

Notes

List of abbreviations

EGFR : 

epidermal growth factor receptor

PE : 

plating efficiency

SF : 

survival fraction

RBE : 

relative biological effect

D0: 

D 0

Dq: 

mean lethal dose

Dq : 

quasithreshold dose

N : 

extrapolation number

MTT : 

methyl thiazolyl tetrazolium

FCM : 

flowcytometry

TKI : 

tyrosine kinase inhibitor

PTEN : 

phosphatase and tensin homolog on chromosome ten

PIP3 : 

phosphatidyinositol-3, 4, 5- triphosphate

PI3K : 

phosphatidylinositol-3-kinase.

Declarations

Acknowledgements

The authors wish to thank Dr. Jan Zhang for his kind review of the manuscript, Dr. Feng Wei for their expert technical assistance, Ms. Min-Yu Wang for her excellent laboratory management. This work was supported by a grant from the Ministry of Civil Affair, China ([2008]18).

Authors’ Affiliations

(1)
Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital and Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China
(2)
Tianjin Lung Cancer Center, Tianjin, PR China

References

  1. Masui H, Kawamoto T, Sato JD: Growth inhibition of human tumor cells in athymicmice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984, 44: 1002-1007.Google Scholar
  2. Yaish P, Gazit A, Gilon C: Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science. 1988, 242: 933-935. 10.1126/science.3263702.View ArticleGoogle Scholar
  3. Gschwind A, Fischer OM, Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer. 2004, 4: 361-370. 10.1038/nrc1360.View ArticleGoogle Scholar
  4. Jose B: Epidermal growth factor receptor pathway inhibitors. Update on cancer therapeutics. 2006, 1: 299-310. 10.1016/j.uct.2006.08.002.View ArticleGoogle Scholar
  5. Fortunato C, Giampaolo T: EGFR Antagonists in Cancer Treatment. N Engl J Med. 2008, 358: 1160-1174. 10.1056/NEJMra0707704.View ArticleGoogle Scholar
  6. Fortunato C, Giampaolo T: Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor. Clinical Cancer Res. 2001, 7: 2958-2970.Google Scholar
  7. Zhu ZP: Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives. Acta Pharmacol Sin. 2007, 28: 1476-1493. 10.1111/j.1745-7254.2007.00681.x.View ArticleGoogle Scholar
  8. Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004, 11: 689-708. 10.1677/erc.1.00600.View ArticleGoogle Scholar
  9. Olivier D, Alexandre , Gerard M: EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors Similarities and differences. Crit Rev Oncol Hemato. 2007, 62: 53-61. 10.1016/j.critrevonc.2006.12.008.View ArticleGoogle Scholar
  10. Kris MG, Natale RB, Herbst RS: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003, 290: 2149-2158. 10.1001/jama.290.16.2149.View ArticleGoogle Scholar
  11. Fukuoka M, Yano S, Giaccone G: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer(The IDEAL 1 Trial)[corrected]. J Clin Oncol. 2003, 21: 2237-2246. 10.1200/JCO.2003.10.038.View ArticleGoogle Scholar
  12. Bonner JA, Harari PM, Giralt J: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006, 354: 567-578. 10.1056/NEJMoa053422.View ArticleGoogle Scholar
  13. Cunningham D, Humblet Y, Siena S: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004, 351: 337-345. 10.1056/NEJMoa033025.View ArticleGoogle Scholar
  14. Haas-Kogan DA, Prados MD, Tihan T: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005, 97: 880-887.View ArticleGoogle Scholar
  15. Mellinghoff IK, Wang MY, Vivanco I: Molecular determinants of the response of glioblastomas to EGFR kinaseinhibitors. N Engl J Med. 2005, 353: 2012-2024. 10.1056/NEJMoa051918.View ArticleGoogle Scholar
  16. Barber TD, Vogelstein B, Kinzler KW: Somatic mutations of EGFR in colorectal cancers and Glioblastomas. N Engl J Med. 2004, 351: 2270-2883. 10.1056/NEJM200412303512724.View ArticleGoogle Scholar
  17. Marie Y, Carpentier AF, Omuro AM: EGFR tyrosine kinase domain mutations in human gliomas. Neurology. 2005, 64: 1444-1445.View ArticleGoogle Scholar
  18. Roberto B, Incheol S, Ritter Christoph: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 2003, 22: 2812-2822. 10.1038/sj.onc.1206388.View ArticleGoogle Scholar
  19. Ingo K, Mellinghoff , Maria Y, Wang P: Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors. N Engl J Med. 2006, 354: 884-897.Google Scholar
  20. Smith Justin, Issei T, Sandra M: PTEN Mutation, EGFR Amplification, and Outcome in Patients With Anaplastic Astrocytoma and Glioblastoma Multiforme. J Natl Cancer Inst. 2001, 93: 1246-1256. 10.1093/jnci/93.16.1246.View ArticleGoogle Scholar
  21. Harima Y, Sawada S, Nagata K: Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy. Int J Oncol. 2001, 18: 493-497.Google Scholar
  22. Endoh H, Yatabe Y, Kosaka T: PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol. 2006, 1: 629-634.View ArticleGoogle Scholar
  23. Baselga J, Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 2005, 23: 2445-2259. 10.1200/JCO.2005.11.890.View ArticleGoogle Scholar
  24. Russell J David Sambrook: olecular Cloning. 2000, America: CSHL Press, 1235-1262. ThirdGoogle Scholar
  25. Fan Z, Masui H, Altas I: Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993, 53: 4322-4328.Google Scholar
  26. Fan Z, Lu Y, Wu X: Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994, 269: 27595-27602.Google Scholar
  27. Prakash C, Shyhmin H, Geetha V: Mechanisms of Enhanced Radiation Response following EpidermalGrowth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva). Cancer Res. 2005, 65: 3328-3335.Google Scholar
  28. Byeong HC, Chang GK, Yoongho L: Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt pathway. Cancer Letters. 2008, 259: 111-118. 10.1016/j.canlet.2007.10.003.View ArticleGoogle Scholar
  29. Ivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2: 489-501. 10.1038/nrc839.View ArticleGoogle Scholar
  30. Liu W, James CD, Frederick L: PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res. 1997, 57: 5254-5257.Google Scholar
  31. Yakut T, Gutenberg A, Bekar A: Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. Oncol Rep. 2007, 17: 1037-1043.Google Scholar
  32. Fiano V, Ghimenti C, Imarisio S: PAkt, cyclin D1 and p27/Kip.1 in glioblastomas with and without EGFR amplification and PTEN mutation. Anticancer Res. 2004, 24: 2643-2647.Google Scholar
  33. Rotterud R, Fossa SD, Nesland JM: Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium. Histol Histopathol. 2007, 22: 349-363.Google Scholar
  34. Pollack IF, Hamilton RL, James CD: Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006, 105: 418-424. 10.3171/jns.2006.105.3.418.View ArticleGoogle Scholar
  35. She QB, Solit DB, Ye Q: The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 2005, 8: 287-297. 10.1016/j.ccr.2005.09.006.View ArticleGoogle Scholar
  36. Tian XX, Zhang YG, Du J: Effects of cotransfection of antisense-EGFR and wild-type PTEN cDNA on human glioblastoma cells. Neuropathology. 2006, 26: 178-187. 10.1111/j.1440-1789.2006.00679.x.View ArticleGoogle Scholar
  37. Kraus JA, Felsberg J, Tonn JC: Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol Appl Neurobiol. 2002, 28: 325-333. 10.1046/j.1365-2990.2002.00413.x.View ArticleGoogle Scholar
  38. Anai S, Goodison S, Shiverick K: Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts. Hum Gene Ther. 2006, 17: 975-984. 10.1089/hum.2006.17.975.View ArticleGoogle Scholar
  39. Lee C, Kim JS, Waldman T: PTEN Gene Targeting Reveals a adiation- Induced Size Checkpoint in Human Cancer Cells. Cancer Res. 2004, 64: 6906-6914. 10.1158/0008-5472.CAN-04-1767.View ArticleGoogle Scholar
  40. Thierry V, Eileen DA, Veronique B: The Egr-1 transcription factor directly activates PTEN during irradiation-induced signaling. Nat Cell Biol. 2001, 3: 1124-1129. 10.1038/ncb1201-1124.View ArticleGoogle Scholar
  41. Tian M, Jin GH, Piao CH: Study on construction of pegfr-hPTEN expression vector induced by irradiation and anti-tumor effect in vitro. Chin J Radiol Prot. 2003, 23: 423-426. 10.1088/0952-4746/23/4/005.View ArticleGoogle Scholar

Copyright

© Zhuang et al; licensee BioMed Central Ltd. 2009

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us